Dr. Markus Grompe is a Professor at the Papé Family Pediatric Research Institute at Oregon Health & Science University in Portland, Oregon, USA. He is a physician-scientist who is clinically active as a biochemical geneticist. Dr. Grompe is scientific founder of two biotechnology companies, Yecuris Corporation (Tigard) and Ambys Medicines (Redwood, CA). His research covers three major topics: 1) Cell and gene therapy for genetic liver diseases; 2) Fanconi’s Anemia and 3) beta-cell replacement therapy for diabetes. For hepatic disorders his lab has focused on in vivo selection to enhance gene and cell transplantation therapy. Recently, he has worked on therapeutic gene editing of hepatocytes in vivo. He developed and commercialized the FRG mouse for the extensive replacement of the liver by human hepatocytes. His lab cloned FANCD2, the lynchpin protein of the Fanconi Anemia DNA repair pathway and developed novel small molecule therapy for this disease. In the diabetes field his lab is known for developing monoclonal antibodies for the viable isolation of all major human pancreatic cell types. Recently, his lab showed that human pancreatic beta-cells exist as four distinct subtypes.  He has published over 200 peer-reviewed articles and holds numerous patents.